Skip to main content

RETRACTION article

Front. Pharmacol., 07 December 2023
Sec. Pharmacology of Anti-Cancer Drugs
This article is part of the Research Topic Multi-targeted Natural Products as Cancer Therapeutics: Challenges and Opportunities, Volume I View all 54 articles

Retraction: Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin

A Retraction of the Original Research Article
Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin

by Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, Gu W, Kui F, Li J, Geng S and Du G (2020). Front. Pharmacol. 10:1658. doi: 10.3389/fphar.2019.01658

The journal retracts the 29 January 2020 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.

Citation: Frontiers Editorial Office (2023) Retraction: Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin. Front. Pharmacol. 14:1349235. doi: 10.3389/fphar.2023.1349235

Received: 04 December 2023; Accepted: 04 December 2023;
Published: 07 December 2023.

Approved by:

Olivier Feron, Université catholique de Louvain, Belgium

Copyright © 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.